Temozolomide (TMZ) combined with radiation therapy is the standard of care for newly diagnosed patients with glioblastoma multiforme (GBM). A key cytotoxic lesion induced by TMZ is repaired by the O6- methylguanine-methyltransferase (MGMT) DNA repair protein, and disruption of MGMT activity significantly increases the sensitivity of tumors to TMZ. Thus, understanding the regulatory mechanisms controlling MGMT activity is of critical clinical importance. An aspect of this regulation that is of fundamental significance involves MGMT methylation, and several studies have demonstrated an association between MGMT promoter methylation and improved GBM patient survival. However, the methylation specific PCR (MS-PCR) reaction that is used most often to interpret MGMT promoter methylation status examines only 9 of 98 potential CpG methylation sites. Because changes in MGMT promoter methylation outside of the region evaluated by MS-PCR can dramatically affect MGMT expression, we hypothesize that a comprehensive evaluation of CpG island methylation will provide a more robust predictor of TMZ response. To further study the influence of MGMT methylation on TMZ sensitivity, the survival benefit of TMZ therapy has been evaluated in an intracranial xenograft therapy model using a panel of 17 human GBMs that were established and maintained by serial passage in the flank of nude mice. Our preliminary data suggest that methylation at 4 MGMT promoter CpG sites, which are not queried by the routinely-used MGMT MS-PCR analysis, is a more accurate predictor of individual tumor TMZ responsiveness. The primary objective of the studies associated with this application is to conclusively address the relationship between GBM response to TMZ and MGMT methylation by identifying the CpG methylation sites that are critical to regulating MGMT expression. For this purpose, the following experimental plan is put forward.
In aim 1, key CpG methylation sites predictive of survival will be identified using GBM tumor specimens from patients treated with TMZ + radiation on 3 prospective clinical trials.
In aim 2, the influence of MGMT methylation patterns on TMZ sensitivity and MGMT mRNA and protein expression will be evaluated our panel of GBM xenografts that collectively recapitulate the range of TMZ responses observed in patient clinical trials.
Aim 3 studies will focus on the use of xenografts for investigating relationships between changes in MGMT CpG methylation patterns and acquired resistance to therapy, which has been observed in association with our preliminary xenograft investigations. In total, this study plan will provide a definitive delineation of MGMT CpG methylation patterns that consistently and reliably predict tumor response to TMZ therapy, and will address the role of changes to MGMT CpG methylation in acquired resistance to TMZ. The addition of temozolomide to standard radiation therapy significantly prolongs survival in a subset of patients with glioblastoma multiforme, which is the most lethal form of brain cancer. The studies planned are designed to develop a robust predictor of temozolomide responsiveness in patients that could be used to customize therapy for patients with this disease. Investigations into the mechanism of temozolomide drug resistance also will provide the foundation for future development of novel temozolomide sensitizing strategies to further improve the cure rate for patients with glioblastoma multiforme

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA127716-05
Application #
8197918
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Nelson, Stefanie A
Project Start
2008-01-01
Project End
2012-12-31
Budget Start
2012-01-01
Budget End
2012-12-31
Support Year
5
Fiscal Year
2012
Total Cost
$372,669
Indirect Cost
$126,032
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Parrish, Karen E; Cen, Ling; Murray, James et al. (2015) Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. Mol Cancer Ther 14:2735-43
Oliva, Claudia R; Markert, Tahireh; Gillespie, G Yancey et al. (2015) Nuclear-encoded cytochrome c oxidase subunit 4 regulates BMI1 expression and determines proliferative capacity of high-grade gliomas. Oncotarget 6:4330-44
Gupta, Shiv K; Mladek, Ann C; Carlson, Brett L et al. (2014) Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. Clin Cancer Res 20:3730-41
Cen, Ling; Carlson, Brett L; Pokorny, Jenny L et al. (2013) Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models. Neuro Oncol 15:735-46
Kitange, Gaspar J; Mladek, Ann C; Carlson, Brett L et al. (2012) Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clin Cancer Res 18:4070-9
Nadkarni, Aditi; Shrivastav, Meena; Mladek, Ann C et al. (2012) ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells. J Neurooncol 110:349-57
Carlson, Brett L; Pokorny, Jenny L; Schroeder, Mark A et al. (2011) Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Curr Protoc Pharmacol Chapter 14:Unit 14.16
Yiin, Jia-Jean; Hu, Bo; Schornack, Paul A et al. (2010) ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain. Mol Cancer Ther 9:929-41
Verhaak, Roel G W; Hoadley, Katherine A; Purdom, Elizabeth et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110
Kitange, Gaspar J; Carlson, Brett L; Schroeder, Mark A et al. (2010) Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance. J Neurooncol 100:177-86

Showing the most recent 10 out of 17 publications